Lyu X P, Yin J, Kong D Q, Tian H, Li Y, Qyu Q, Su J, Cao L J, Bai X, Yu Z Q, Wang Z Y, Wu D P, Ruan C G
Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Disease, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215006, China.
Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):43-47. doi: 10.3760/cma.j.issn.0253-2727.2023.01.008.
To report the clinical manifestations and laboratory features of five patients with congenital thrombotic thrombocytopenic purpura (cTTP) and explore its standardized clinical diagnosis and treatment along with a review of literature. Clinical data of patients, such as age of onset, disease manifestation, personal history, family history, and misdiagnosed disease, were collected. Treatment outcomes, therapeutic effects of plasma infusion, and organ function evaluation were observed. The relationship among the clinical manifestations, treatment outcomes, and ADAMTS13 gene mutation of patients with cTTP was analyzed. Additionally, detection of ADAMTS13 activity and analysis of ADAMTS13 gene mutation were explored. The age of onset of cTTP was either in childhood or adulthood except in one case, which was at the age of 1. The primary manifestations were obvious thrombocytopenia, anemia, and different degrees of nervous system involvement. Most of the patients were initially suspected of having immune thrombocytopenia. Acute cTTP was induced by pregnancy and infection in two and one case, respectively. ADAMTS13 gene mutation was detected in all cases, and there was an inherent relationship between the mutation site, clinical manifestations, and degree of organ injury. Therapeutic or prophylactic plasma transfusion was effective for treating cTTP. The clinical manifestations of cTTP vary among individuals, resulting in frequent misdiagnosis that delays treatment. ADAMTS13 activity detection in plasma and ADAMTS13 gene mutation analysis are important bases to diagnose cTTP. Prophylactic plasma transfusion is vital to prevent the onset of the disease.
报告5例先天性血栓性血小板减少性紫癜(cTTP)患者的临床表现和实验室特征,探讨其规范化临床诊断与治疗方法,并进行文献复习。收集患者的临床资料,如发病年龄、疾病表现、个人史、家族史及误诊疾病等。观察治疗结果、血浆输注的治疗效果及器官功能评估情况。分析cTTP患者的临床表现、治疗结果与ADAMTS13基因突变之间的关系。此外,探讨ADAMTS13活性检测及ADAMTS13基因突变分析。cTTP的发病年龄除1例为1岁外,其余均在儿童期或成年期。主要表现为明显的血小板减少、贫血及不同程度的神经系统受累。多数患者最初被怀疑患有免疫性血小板减少症。急性cTTP分别由妊娠和感染诱发,各2例和1例。所有病例均检测到ADAMTS13基因突变,且突变位点、临床表现及器官损伤程度之间存在内在联系。治疗性或预防性血浆输注对治疗cTTP有效。cTTP的临床表现因人而异,导致误诊频繁,延误治疗。血浆ADAMTS13活性检测及ADAMTS13基因突变分析是诊断cTTP的重要依据。预防性血浆输注对预防该病发作至关重要。